Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
BMC Bioinformatics|April 14, 2007
Environment specific substitution tables for thermophilic proteinsK Mizuguchi, M Sele, M V CubellisACS Medicinal Chemistry Letters|October 18, 2019
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine MoietyChiara Borsari, Denise Rageot, Florent Beaufils, et al.Neuropharmacology|August 7, 2018
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsyClaudia Brandt, Petra Hillmann, Andreas Noack, et al.Journal of Medicinal Chemistry|August 30, 2019
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR InhibitorChiara Borsari, Denise Rageot, Alix Dall'Asen, et al.Journal of Medicinal Chemistry|October 26, 2018
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological DisordersDenise Rageot, Thomas Bohnacker, Anna Melone, et al.Journal of Medicinal Chemistry|June 28, 2019
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR KinaseDenise Rageot, Thomas Bohnacker, Erhan Keles, et al.Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.Pageof 1